News/ News/ R&D Reata rockets on data for Nrf2 drug reacquired from AbbVie Phil Taylor AbbVie, omaveloxolone, rare disease, Reata Pharma 0 Comment Reata Pharma has reported positive clinical results with one of its Nrf2 activators for mitochondrial diseases, just days Share X Reata rockets on data for Nrf2 drug reacquired from AbbVie https://pharmaphorum.com/news/reata-rockets-on-data-for-nrf2-drug-reacquired-from-abbvie/
